Cefepime/Nacubactam is a combination medication used in this study to treat various serious infections. Cefepime is an antibiotic that helps kill bacteria, while Nacubactam enhances the effectiveness of Cefepime by inhibiting certain enzymes that bacteria use to resist antibiotics. This combination is administered through an intravenous infusion to treat complicated urinary tract infections, acute uncomplicated kidney infections, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, and complicated intra-abdominal infections caused by resistant bacteria.

Aztreonam/Nacubactam is another combination medication being tested in the trial. Aztreonam is an antibiotic that targets and kills bacteria, and Nacubactam works alongside it to block bacterial resistance mechanisms. This combination is also given through an intravenous infusion and is aimed at treating the same types of serious infections as the Cefepime/Nacubactam combination, particularly those caused by bacteria that are resistant to other antibiotics.

Complicated Urinary Tract Infection (cUTI) – This condition involves infections of the urinary tract that are associated with structural or functional abnormalities, making them more difficult to treat. It can affect the bladder, kidneys, or both, and may lead to more severe symptoms than uncomplicated infections. Patients may experience frequent urination, pain during urination, and abdominal pain. The infection can progress to the kidneys, causing more severe symptoms like fever and back pain.

Acute Uncomplicated Pyelonephritis (AP) – This is a sudden and severe kidney infection that typically occurs in healthy individuals with no structural or functional urinary tract abnormalities. It often starts as a bladder infection and progresses to the kidneys, causing symptoms such as high fever, chills, and flank pain. The condition can lead to nausea and vomiting, and requires prompt medical attention to prevent complications.

Hospital-Acquired Bacterial Pneumonia (HABP) – This type of pneumonia is acquired during a hospital stay, typically 48 hours or more after admission. It is caused by bacteria and can lead to symptoms such as cough, fever, and difficulty breathing. The condition can progress rapidly, especially in patients with weakened immune systems or underlying health issues.

Ventilator-Associated Bacterial Pneumonia (VABP) – This pneumonia occurs in patients who are on mechanical ventilation for at least 48 hours. It is caused by bacteria that enter the lungs through the ventilator tube, leading to symptoms like fever, increased respiratory secretions, and changes in lung function. The condition can complicate the recovery of critically ill patients.

Complicated Intra-Abdominal Infection (cIAI) – This infection occurs within the abdominal cavity and involves multiple organs, often following surgery or trauma. It can lead to symptoms such as severe abdominal pain, fever, and nausea. The infection can spread to other parts of the body, making it more challenging to manage.